ACADIA PHARMACEUTICALS INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
ACAD$18.28+10.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Total stockholders’ equity, beginning balances | $516,700 | $395,793 | $431,755 | $400,413 |
| Common stock: | ||||
| Beginning balance | 16 | 16 | 16 | 16 |
| Ending balance | 16 | 16 | 16 | 16 |
| Additional paid-in capital: | ||||
| Beginning balance | 2,897,916 | 2,807,770 | 2,862,552 | 2,770,923 |
| Issuance of common stock from exercise of stock options and units | 268 | 12,751 | 1,384 | 17,032 |
| Issuance of common stock pursuant to employee stock purchase plan | — | — | 3,492 | 2,663 |
| Stock-based compensation | 26,250 | 18,590 | 57,006 | 48,493 |
| Ending balance | 2,924,434 | 2,839,111 | 2,924,434 | 2,839,111 |
| Accumulated deficit: | ||||
| Beginning balance | (2,380,893) | (2,411,458) | (2,430,837) | (2,369,551) |
| Net income (loss) | 32,765 | (65,176) | 82,709 | (107,083) |
| Ending balance | (2,348,128) | (2,476,634) | (2,348,128) | (2,476,634) |
| Other comprehensive income (loss): | ||||
| Beginning balance | (339) | (535) | 24 | (975) |
| Other comprehensive income (loss) | 1,197 | 216 | 834 | 656 |
| Ending balance | 858 | (319) | 858 | (319) |
| Total stockholders’ equity, ending balances | $577,180 | $362,174 | $577,180 | $362,174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.